The pharmacokinetics of intravenous ciprofloxacin 400 mg 12 hourly in patients with severe sepsis: the effect of renal function and intra-abdominal disease.
Serum concentrations of ciprofloxacin were reviewed in 22 patients given ciprofloxacin 400 mg intravenously 12 hourly for severe infection. No dosage modifications were made in patients with renal impairment. Patients who had either bowel or liver pathology in addition to renal failure had significantly higher serum concentrations than all other patients. Dosage reduction of ciprofloxacin in patients with severe sepsis and impaired renal function is not required unless they have co-existent intra-abdominal disease.
Jones
E M
EM
Bristol Centre for Antimicrobial Research and Evaluation, Southmead Health Services NHS Trust and the University of Bristol, Southmead Hospital, Westbury-on-Trym, UK. lesassays@ukneqasaa.win-uk.net
McMullin
C M
CM
Hedges
A J
AJ
Lovering
A M
AM
White
L O
LO
Reeves
D S
DS
MacGowan
A P
AP
D000005:Abdomen / Q000503:physiopathology*; D000328:Adult; D000368:Aged; D016470:Bacteremia / Q000150:complications / Q000188:drug therapy*; D002939:Ciprofloxacin / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D003401:Creatine / Q000097:blood; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007362:Intensive Care Units; D007668:Kidney / Q000187:drug effects / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D051437:Renal Insufficiency / Q000188:drug therapy
D002939:Ciprofloxacin; D003401:Creatine